Allogene Therapeutics (ALLO) News
NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALLO news summary
We found 6 recent headlines mentioning Allogene Therapeutics (ALLO): 1 in the past week and 6 in the past 30 days, most often from GlobeNewswire. ALLO is making an outsized move today, down 5.88% at $0.6277, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access", was published by GlobeNewswire on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Allogene Therapeutics headlines
- Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient AccessSOUTH SAN FRANCISCO, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire
- Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune DiseaseSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire
- Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdateSOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire
- Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual MeetingSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire
- Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical DataSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T…GlobeNewswire